Modeling breast cancer proliferation, drug synergies, and alternating therapies

Estrogen receptor positive (ER+) breast cancer is responsive to a number of targeted therapies used clinically. Unfortunately, the continuous application of targeted therapy often results in resistance, driving the consideration of combination and alternating therapies. Toward this end, we developed...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Wei, Demas, Diane M., Shajahan-Haq, Ayesha N., Baumann, William T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206440/
https://www.ncbi.nlm.nih.gov/pubmed/37234088
http://dx.doi.org/10.1016/j.isci.2023.106714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206440/
https://www.ncbi.nlm.nih.gov/pubmed/37234088
http://dx.doi.org/10.1016/j.isci.2023.106714

Ejemplares similares